More Breast Cancer Patients Than Previously Thought Could Benefit from PARP Inhibitors

PARP inhibitors like Lynparza (olaparib) were designed to treat patients with inherited BRCA1 or BRCA2 mutations, but more women with breast cancer could benefit from these drugs, a study suggests. The team found that up to 22 percent of breast cancer patients had mutations that led to a defective BRCA function — a much higher percentage than the 1 to 5 percent of women known to have BRCA mutations. While the results must be validated in future clinical trials, the findings suggest that a much larger percentage of breast cancer patients could benefit from already approved PARP inhibitors.

Breast Cancer-related Clinical Trial Controversy Resurfaces

In his article, “The evidence base for HRT: what can we believe?,” Professor Robert D. Langer argues that a small group of the study’s investigators “hijacked” the data. One of his accusations is that the group incorrectly reported that the study was cut short because of higher risks of women developing breast cancer and heart attacks from the hormonal treatment. The serious allegations against some of the investigators in the Women’s Health Initiative (WHI; NCT00000611) suggest that the study reporting violated guidelines on how trial data should be presented.

Cancer Linked to Gut Health

Until 2014 scientists had no reason to believe that bacteria might play any role at all in breast cancer. But then a Canadian, Dr. Gregor Reid, a scientist at Lawson Health Research Institute, felt that this since mothers impart bacteria to their children from breast milk, and the longer a mother breast feeds the more protection she gives herself, maybe there were bacterial factors at work in breast cancer. Sure enough, Dr. Reid and his doctoral student Camilla Urbaniak from Western University, Ontario, Canada, showed that your breasts do have their own set of live bacteria – their own microbiome.

How to Find Support for Advanced Breast Cancer

Advanced breast cancer, also called stage 4 breast cancer, can be challenging to live with. In addition to enduring the physical toll of cancer and its treatment, you might also experience emotional highs and lows. Treatment can slow the cancer’s progression for months or years, according to the American Cancer Society (ACS), which means you may need support over a long period of time. But it’s important to know that you don’t have to go it alone. There are many resources and sources of support available to help you better manage advanced breast cancer. Here’s how to find the emotional and practical support you need for your journey.

Afinitor May Keep Breast Cancer Patients on Chemo Fertile

A major concern for premenopausal women who have chemotherapy is infertility. That’s because the treatment can damage the ovaries and reduce the supply of ovarian follicles, precursors of egg cells that are needed for future pregnancies. “Our results argue that everolimus may represent a fertility-sparing drug treatment to complement the freezing of eggs and embryos, which are valued methods, but time-consuming, costly, less effective with age, and not protective of long-term ovarian function,” Goldman said.

Are Hazardous Waste Sites to Blame for Cancer Hot Spots?

“Our goal was to determine if there were differences or associations regarding cancer incidence in counties that contain Superfund sites compared to counties that do not,” said Dr. Emily Leary, study co-author, in a press release. “We found the rate of cancer incidence increased by more than 6 percent in counties with Superfund sites.”

Aggressive Breast Cancer Therapy Shows Promise in Clinical Trial

Thirty percent of patients with metastatic triple-negative breast cancer (TNBC) responded to the experimental therapy sacituzumab govitecan after failing to respond to other treatments, according to Phase 2 trial results. Other measures of its effectiveness included the length of time patients responded to treatment, overall patient survival rate, and time to progression. The therapy was also well-tolerated, the team added.

Early State Breast Cancer Therapy Decapeptyl Wins British Approval

Britain has approved Ipsen Pharmaceuticals’ Decapeptyl (triptorelin) in combination with tamoxifen or an aromatase inhibitor to treat pre-menopausal, early stage breast cancer patients. St Gallen, the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO) updated their early stage breast cancer treatment guidelines. The new guidelines include a recommendation that an ovarian function suppressor be used in combination with tamoxifen or Aromasin to treat these patients.

8 Ways To Detox Your Home 

We are exposed to more synthetic chemicals in our food, air and water, than ever before. While many people avoid chemicals in their food, the sad fact remains that most people aren’t aware of the nasty toxins they may inadvertently invite into their homes. While there really are countless ways to give your home a detox, here are 8 of the best ways to eliminate excess toxins from your home:

Breast Cancer Detected with 100% Accuracy by Dogs Sniffing Clothing, French Team Says

German shepherds, with training, were able to detect breast cancer in women by sniffing a piece of clothing that they had worn close to a breast with a tumor, French researchers at the Curie Institute in Paris report. The dogs, after only six months of training, were 100 percent accurate in detecting breast cancer — opening the possibility of a highly non-invasive, and low cost, means of spotting a possible cancer, particularly in regions where mammograms are scarce or non-existent.

What Are Targeted Therapies for Breast Cancer? 

Targeted therapies for breast cancer are drugs or treatments that block the spread and growth of cancer cells by targeting the molecules responsible for the cancer’s growth. There are different target therapies for different types of cancer There are various targeted therapies currently used for the treatment of breast cancer including signal transduction inhibitors, apoptosis inducers, immunotherapies, gene expression modulators and hormone therapies, all of which work slightly differently to kill the cancer cells.

The Presence of a Molecular Marker May Predict Breast Cancer for Early Treatment 

Ki67 is a molecular marker found in the lining of the mammary ducts and milk-producing lobules that identifies proliferating cells. These tissues are the site where most breast cancers develop. While Ki67 testing is already being used to determine courses of treatment, this discovery will allow doctors to test precancerous tissue for use as a predictive tool. The method could help avoid some of the drawbacks of mammograms, which are currently the best option for early detection.

Mammography vs. thermography: Comparing the benefits

Opinion at this point seems to be that thermography is not a replacement for screening mammography. Most experts continue to recommend getting a regular mammogram according to the national guidelines or as advised by a health care professional. However, the risks of mammography should not be taken lightly, and the search for new alternative methods of screening should continue. Whatever the screening options available, women should be supported in making informed decisions about how often they want to be screened, and which screening method is right for them.